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Gastroretentive dosage forms extend significantly the period of 
time over which the drug may be released. This prolonged gastric 
retention improves bioavailability, decrease drug waste and improve 
solubility of drugs that are less soluble in a high pH environment due 
to their availability in gastric pH for longer duration of time.Floating 
drug delivery systems have a bulk density less than gastric fluids and 
hence remain buoyant in the stomach. The main objective of the 
present study was to develop Gastroretentive (GR) controlled release 
formulations of Metoprolol to prolong the gastric retention time so 
that its bioavailability can be improved. The formulations were 
prepared by using swellable polymers like HPMC K4M, HPMC K15M, 
HPMC K100M, Guar Gum, Xanthan Gum, Sodium carboxymethyl 
cellulose and various effervescent compounds, e.g. sodium 
bicarbonate, and citric acid by the direct compression method. All the 
formulations were evaluated for different parameters like floating lag 
time, total floating time, hardness, weight variation, density 
measurements, drug content and  water uptake/swelling index. 
Dissolution studies were done for all formulations in 0.1N HCl (pH 
1.2). Formulations F3, F4 and F10 were found to provide maximum 
sustained release of metoprolol s uccinate up to 24 h with optimum 
floating properties.  
 




Oral delivery of drug is the most 
preferable route of drug delivery due to the 
ease of administration, patient compliance and 
flexibility in formulation, etc. Conventional 
drug delivery system sachieve as well as 
maintain the drug concentration within the 
therapeutically effective range needed for 
treatment only when taken several times a day, 
which can lead to significant fluctuations in 
drug levels (Gupta et al., 2010). 
Attempts are being made to develop a 
single dose therapy for the complete duration 
of treatment, where focus is mainly on the 
controlled or sustained release drug delivery 
systems because of the ease of the 
administration via the oral route as well as the 
ease and economy of manufacture of oral 
dosage forms (Hoffman, 1998). 
One requisite for successful performance 
of oral controlled release drug delivery system 
is that drug should have good absorption 
throughout the GIT, preferably by passive 
diffusion. Oral controlled release dosage forms 
are not suitable for many drugs, characterized 
by a narrow absorption window in the upper 
part of GIT (Stomach & small intestine). This 
is due to the relatively short transit time of the 
dosage form in these anatomical segment i.e. 6 
hrs. (Patil et al., 2006). 
G.I. transit times vary widely between 
individuals, and depend up on the physical 
properties of the object ingested and the 
physiological conditions of the gut. This 
variability may lead to unpredictable 
bioavailability and times to achieve peak plasma 
levels (Longer et al., 1985). 
Therefore, in cases where the drug is not 
absorbed uniformly over the G.I tract, the rate 
of drug absorption may not be constant. In 
spite of the drug delivery system, delivering the 
drugs at a constant rate into the G.I fluids, it 
may cause incomplete drug release from the 
dosage form at absorption sites,thus leading to 
diminished efficacy of the administered dose 
(Klausner et al., 2003). 
It is apparent that for a drug having such 
an absorption window, an effective orally 
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controlled drug delivery system should be 
designed not only to deliver the drug at a 
controlled rate, but also to retain the                
drug in the stomach for a long period               
of time (Mojaverian et al., 1988). After oral 
administration, such a dosage form would be 
retained in the stomach and release the drug 
there in a controlled and prolonged manner, so 
that the drug could be supplied continuously to 
its absorption sites in the upper gastro intestinal 
tract (Singh and Kim, 2000). Incorporation of 
the drug in a controlled release gastro retentive 
dosage form (CRGRDF) can yield significant 
therapeutic advantages due to a variety of 
pharmacokinetic and pharmacodynamic factors 
(Timmermans and Moes, 1994).  
Controlled release Gastroretentive drug 
delivery systems (GRDDS) are the systems 
which are retained in the stomach for a 
prolonged period of time and thereby 
improved the bio availability. GRDFs extend 
significantly the period of time over which the 
drugs may be released. They not only prolong 
dosing intervals, but also increase patient 
compliance beyond the level of existing 
controlled release dosage form (Sharma et al., 
2011). 
Effervescent drug delivery system 
utilizes matrices prepared with swellable 
polymers such as methocel or polysaccharides 
and effervescent components like sodium 
bicarbonate and citric or tartaric acid. Different 
formulations of metoprolol succinate were 
prepared by using cellulosic hydrocolloids of 
different viscosity grades HPMC (K4M, K15M 
and K100M) and gel forming hydrocolloids 
natural polymers like Guar Gum and Xanthan 
Gum for sustained release. 
Metoprolol succinate is a β-1-selective 
adrenergic blocking agent. The half-life of 
metoprolol Succinate is about 3-4 hrs, hence 
the multiple doses are needed to maintain a 
constant plasma concentration for a good 
therapeutic response and improved patient 
compliance. It has also been reported that drug 
absorption mainly takes place in the duodenum 
and jejunum and is directly proportional to the 
dose available.  
 
MATERIAL AND METHODS 
Metorpolol succinate was received as a 
gift sample from Ranbaxy Drug Laboratories, 
Gurgaon (HR), India. The polymers HPMC 
K4M, HPMC K15M and HPMC K100M were 
received from Colorcon Asia Pvt. Ltd., Goa, 
India. Guar gum, sodium bicarbonate, sodium 
carboxy methyl cellulose, citric acid and 
magnesium stearate were procured from S.D. 
Fine Chemicals Pvt. Ltd., Ahmedabad (Guj), 
India. All other chemicals and reagents used 




Drug polymer interaction study 
This study was carried out by taking the 
FTIR spectrum of samples of drug and 1:1 
mixture of drug and polymer. The FTIR of the 
samples of drug and mixture were taken in KBr 
pellets. The pellets were scanned over a wave 
number range of 4000 to 400 cm-1. The UV 
spectroscopy was carried out by dissolving the 
drug in   0.1 N HCl (pH=1.2) and scanned at 
wavelength 222.0nm. 
The tablets excipients were choosen 
after comprensive drug-polymer interaction 
study. 
Preparation of floating tablets of metoprolol 
succinate 
Different compositions of floating 
tablets of Metoprolol Succinate with         
different polymers were prepared by the         
direct compression method (Table I). All 
ingredients were powdered, weighed and mixed 
properly. Magnesium stearate was added as a 
lubricant.  
Evaluation of floating tablets of metoprolol 
succinate floating behavior 
In vitro floating behavior of tablet          
was studied by placing the tablet in               
500mL container filled with 300mL 0.1N HCl 
(pH=1.2) and the time taken by tablet to          
float on the surface was recorded as floating  
lag time and the total duration of time in              
which the tablet was floated in the             
dissolution medium was the total floating           
time and were determined by visual 
observation. 
Determination of tablet hardness  
The crushing strength of tablet was 
measured by Monsanto tablet hardness tester 
which applies compression force diametrically 
to the tablets. The force required to crush the 
tablet was recorded as hardness of tablet in 
kg/cm2. 
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Determination of tablet friability 
The friability was determined by 
weighing 10 tablets and placing them in a 
Roche type friability apparatus and rotating it at 
25 rpm for 4 minutes (i.e.100 drops). After 
dusting tablets were weighed for their final 
weight and % friability was calculated as 
follows: 
(weightinitial- weightfinal) %friabilty: [ 
weightinitial] 
]× 100 
Measurement of tablet density  
To check the floating behavior of tablets 
the apparent densities of the tablets were 
calculated from their volume and mass. The 
volume of the tablets were calculated from their 
heights ‘h’ and radii ‘r’ (both determined by 
using a micrometer gauge by using the 
mathematical equation for a cylinder {V= 
πr2h}. 
Weight variation  
Twenty tablets of each formulation were 
weighed individually and their mean weight and 
standard deviation from mean weight was 
calculated.  
Other physical parameters 
Four tablets of each formulation were 
examined for their diameter, thickness and 
height of tablets by using micrometer gauge. 
 
In - vitro drug release study 
Release study of floating tablets were 
carried out in 900mL of 0.1N HCl buffer of 
pH=1.2 dissolution medium using USP 
apparatus II at 37°C with paddle speed at 75 
rpm. The floating tablets of metoprolol 
succinate were weighed and dropped into the 
dissolution medium. During dissolution study, 
every time 5 ml of aliquots of dissolution 
medium were withdrawn and replaced with 5 
ml of fresh medium kept at 37°C. These 
samples were filtered and the required dilutions 
were made with the 0.1N HCl solution of 
pH1.2 and then analyzed at λmax 222.0nm using 
UV-visible spectrophotometer. 
Table I. Different compositions of floating tablets of metoprolol succinate 
 
 F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
Drug 200 200 200 200 200 200 200 200 200 200 
Sodium CMC 20 20 20 20 20 20 20 20 20 20 
Xanthan Gum - 20 - 20 - - - - - - 
Guar Gum 20 - 20 - - - - - - - 
HPMC K100M - - - - 20 20 - - - - 
HPMC K4M 110 110 - - 110 - 130 - - 160 
HPMC K15M - - 110 110 - 110 - 130 160 - 
Sodium Bicarbonate 70 70 70 70 70 70 70 70 70 70 
Citric Acid 30 30 30 30 30 30 30 30 - - 
Magnesium Stearate 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 
 










Mean ± S.D. 
(n= 3) 
Weight (mg) 
Mean ± S.D 
(n=20) 
Height (mm) 
Mean ±  S.D 
(n= 3) 
F1 4.3 0.75 10.75 ± 0.01 454 ± 0.99 5.06 ± 0.01 
F2 4.7 0.42 10.78 ± 0.03 460 ± 1.65 5.06 ± 0.07 
F3 4.7 0.45 10.70 ± 0.02 460 ± 2.32 5.09 ± 0.04 
F4 4.6 0.43 10.70 ± 0.01 450 ± 1.84 5.25 ± 0.5 
F5 4.4 0.36 10.70 ± 0.01 452 ± 1.33 5.12 ± 0.02 
F6 4.4 0.45 10.66 ± 0.02 449 ± 1.42 5.13 ± 0.04 
F7 4.6 0.75 10.83 ± 0.02 455 ± 1.55 5.13 ± 0.05 
F8 4.5 0.44 10.67 ± 0.02 450 ± 0.99 5.14 ± 0.04 
F9 4.6 0.46 10.73 ± 0.02 457 ± 1.83 5.06  ± 0.05 
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RESULTS AND DISCUSSION 
Drug polymer interface study 
Drug Polymer Interface studywas carried 
out to eliminate the possibility of interaction of 
polymers like HPMC K4M, HPMC K15M, 
HPMC K100M, Guar Gum, Xanthan Gum, 
Sodium carboxymethyl cellulose with 
Metoprolol Succinate. The UV Scan and FTIR 
spectra are shown in figure 1 and 2 respectively. 
The peak position for FTIR spectra in case of 
1:1 mixture of drug and polymer are same as in 
the pure drug and pure polymers, the 
representative spectrum of 1:1 mixture of 
metoprolol succinate and HPMC K 15M is 
shown in figure 4.  In addition to it none of the 
polymer tends to shift the λmax of Metoprolol 
Succinate. 
Evaluation of floating tablets of 
metoprolol succinate 
Physical evaluation and assay of floating tablets 
Hardness, friability and weight variation 
parameters were evaluated and results are given 
in table II. All these measured parameters of 
floating tablets of metoprolol succinate were 
within the USP limits. 
When the compression force of the 
tablet compressing machine increases, hardness 
of the tablets increases which results in the 
reduction of floating behaviour of the tablets, 
that may be due to the reduction of the 
porosity of tablets and the compacted polymer 
particles on the surfaces of the tablets cannot 
hydrate rapidly when the tablet contacts the 
gastric fluid. On the other hand, if the hardness 
 
 




Figure 2. FTIR spectra of Metoprolol Succinate 
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too low for the tablets, they will be friable and 
therefore not acceptable. The hardness of all 
formulations was found to be in the range of 4-
5Kg/cm2, which were well within the USP 
limits. 
Floating behaviour of the tablets  
On immersion in 0.1N HClsolution 
(pH1.2) at 37°C, all the tablets first sank in the 
release medium and then they float to the 
surface. Floating lag time was measured for all 
the formulations and it was observed that the 
tablets were floats within 30-42secs. and remain 
buoyant up to 24h (Table III).  
Density measurements  
TThe density of floating tablets         
were found uniform among different          
batches and ranged from 0.98-1.01gm/cm3 
(Table III). All the formulations were found           














Figure 5In vitro dissolution profile of formulations F1-F5. 
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In vitro drug release studies 
All the tested formulations showed 
sustained release patterns of metoprolol 
succinate for 24h. The amount of drug 
(Metoprolol Succinate), polymer (Sodium 
CMC) and effervescence producing agent 
(Sodium Bicarbonate) was kept constant. 
It was observed that F1 releases the 99% 
of the total drug content within the 16h. In 
order to sustain the release of drug from tablets 
more effectively, formulations with different 
viscosity grades of HPMC and with the 
combinations of Sodium CMC, Xanthan Gum 
and Guar Gum were prepared. The more 
sustained release of the drug was observed in 
case of the formulations F2 and F3. Guar gum 
produced lesser sustained release formulation. 
However F4 shows the 99.08% drug 
release after 24 hrs. Here more sustained effect 
was produced with X-Gum and HPMC K15M.  
F5- F10 formulations were prepared by 
using the different viscosity grades of HPMC 
K4M, HPMC K15M and HPMC K100M,in 
spite of using Xanthan gum or Guar Gum. 
These formulations showed the better 
sustained release effect. Formulation F5 (20mg 
of HPMC K100M + 110mg of HPMC K4M) 
releases the 96% drug in 16h and 99.8% drug in 
20h. The similar results were obtained by using 
the HPMC K100M. 
F6 (20 mg of HPMC K 100M + 110mg 
of HPMC KM 15) releases the 96.2% drug in 
16h and 99.9% drug in 20h. The higher 
concentrations of HPMC K4M and HPMC K 
15M were used to obtain the more sustained 
release effect. Here, F7 (130 mg of HPMC 
K4M) releases the 97.4% drug in 20 hrs and 
almost 100% drug in 24 hrs and F8 (130 mg of 
HPMC K15M) releases about 99.3% drug in 
20h. The results obtained were quite similar.  
 
 
Figure 6In vitro dissolution profile of formulations F6-F10. 
 




Floating Lag Time (Sec.) Floating Duration (h) 
Density 
(gm/cm3) 
F1 30 Up to 24 1.012 
F2 34 Up to 24 0.995 
F3 38 Up to 24 0.998 
F4 40 Up to 24 0.982 
F5 35 Up to 24 0.979 
F6 42 Up to 24 0.981 
F7 39 Up to 24 1.012 
F8 31 Up to 24 0.996 
F9 34 Up to 24 1.001 
F10 35 Up to 24 0.994 
 
Formulation and in Vitro Evaluation 
Volume 24 Issue 3 (2013) 176 
However, sustained release effect was 
obtained in case of F9 and F10. F9 (160 mg of 
HPMC K15M) releases about 97.7% drug in 24 
hrs and F10 (160 mg of HPMC K4M) releases 
about 100% drug in 24 hrs.  
The net effect of viscosity enhancing 
agents as well as swelling effect produced by 
the various polymers produced the gastro 
retentive dosage form for 24 hours. 
 
CONCLUSION 
The floating drug delivery is promising 
approaches to achieve sustain release. The 
addition of swell able gel-forming polymers like 
HPMC K4M, HPMC K15M, HPMC K100M, 
Guar Gum, Xanthan Gum, Sodium 
carboxymethyl cellulose and gas-generating 
agent sodium bicarbonate was essential to 
achieve in vitro buoyancy. Addition of citric 
acid, to achieve buoyancy under the elevated 
pH of the stomach, caused an enhancement in 
drug release. Polymers welling is crucial in 
determining the drug release rate and is also 
important for flotation. A lesser floating lag 
time and prolonged buoyancy duration could 
be achieved by varying the amount of different 
polymer combinations. 
From floating and drug release behavior, 
it can be concluded that sustained release 
floating matrix tablets of metoprolol succinate 
can be formulated using HPMC K15M or 
HPMC K4M in combination with other 
polymers and gas generating agents for 
prolonged residence and controlled release of 
the drug. Thus, the current study resulted in 
successful development of once-a-day 
controlled release gastro retentive formulations 
of metoprolol succinate. 
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